Compare Biogen Inc (BIIB) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Biogen Inc trades at $204 (market cap $30.13B), while Regeneron Pharmaceuticals Inc trades at $796.8 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.7× Biogen Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | REGN | |
|---|---|---|
Market Cap | $30.13B | $82.06B |
Sector | Health | Health |
52-Week High | $216.63 | $812.27 |
52-Week Low | $128.93 | $555.51 |
Enterprise Value | $37.20B | $76.77B |
Dividend Yield | — | 0.47% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
